UK Medtechs Stress Need To Get It Right On Brexit As Prime Minister Addresses EU
Executive Summary
Coinciding with UK prime minister Theresa May's third major speech on her Brexit vision for the UK, the local medtech industry has taken the opportunity to stress the vital need for sensible, workable trading arrangements governing UK-EU health-care supply chains after March 2019.
You may also be interested in...
UK Medtechs Get A Touch More Certainty With Brexit Transition Agreement
With the UK scheduled to leave the EU one year, the UK medtech and lifesciences industries were becoming increasingly concerned about the government's lack ofplanning and the risk of being left high and dry in the post-Brexit environment. But the UK has bought more time now that the EU agreed to a withdrawal transition phase until the end of 2020. There are potentially meaningful positives in the agreement for medtechs on either side of the English Channel.
UK Outlook 2018: Companies Need To Quantify Brexit Risk And Find A New Place In The World
With the clock running down on Brexit, bemused UK medtechs are ready to seize any information that helps them chart a way forward on trading with the EU in the absence of solid directions from the government. Frustrated by the Brexit vacuum, local manufacturers are actively looking to build businesses beyond the EU and focusing on innovation adoption at home, as ABHI policy director Richard Phillips explains.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.